drugset / Trial / NCT00314977

Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

NCT00314977 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

2 different treatment schedules may be used for neoadjuvant chemotherapy in breast cancer using adriamycin, cyclophosphamide and taxotere. The most optimal sequence- concurrent or sequential- is however unclear. The aim of the study is to compare the efficacy and tolerability of neoadjuvant chemotherapy with AC followed by T(adriamycin, cyclophosphamide, taxotere) versus TAC ( with upfront T) in patient with large resectable or locally advanced breast cancer.

Timeline

Start
2006-02
Primary completion
2009-04
Completion
—

Outcome

Missed primary endpoint

paper CONCLUSIONS: No differences were observed between the two treatment arms with respect to pCR rate PMID 28674765 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 500 mg/m2 —
Subject Cyclophosphamide Other / unclassified 6000 mg/m2 —
Subject Docetaxel Small molecule 75 mg/m2 —
Subject Docetaxel Small molecule 100 mg/m2 —
Subject Doxorubicin Other / unclassified 50 mg/m2 —
Subject Doxorubicin Other / unclassified 60 mg/m2 —

Indications